EGFR and central nervous system cancer: Co-evaluating histological grade and EGFR amplification status showed that grade could prognostically separate EGFR non-amplified lower-grade gliomas (p < 0.0001) but not EGFR amplified lower-grade gliomas (p < 0.811) (Fig. 3f).